AR126166A1 - Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos - Google Patents

Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos

Info

Publication number
AR126166A1
AR126166A1 ARP220101591A ARP220101591A AR126166A1 AR 126166 A1 AR126166 A1 AR 126166A1 AR P220101591 A ARP220101591 A AR P220101591A AR P220101591 A ARP220101591 A AR P220101591A AR 126166 A1 AR126166 A1 AR 126166A1
Authority
AR
Argentina
Prior art keywords
inhibitor
kras
combination
erk
pharmaceutically acceptable
Prior art date
Application number
ARP220101591A
Other languages
English (en)
Spanish (es)
Inventor
Bing Hou
Jian Wang
Bo Shan
Xingxing Wang
Yun Liu
Peng Chen
Hui Yuwen
Bin Jiang
Jay Mei
Original Assignee
Antengene Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antengene Discovery Ltd filed Critical Antengene Discovery Ltd
Publication of AR126166A1 publication Critical patent/AR126166A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
ARP220101591A 2021-06-18 2022-06-16 Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos AR126166A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021100892 2021-06-18
CN2022095820 2022-05-28

Publications (1)

Publication Number Publication Date
AR126166A1 true AR126166A1 (es) 2023-09-27

Family

ID=84526853

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101591A AR126166A1 (es) 2021-06-18 2022-06-16 Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos

Country Status (4)

Country Link
CN (1) CN117529321A (fr)
AR (1) AR126166A1 (fr)
TW (1) TW202317130A (fr)
WO (1) WO2022262797A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023137223A1 (fr) * 2022-01-17 2023-07-20 Newave Pharmaceutical Inc. Inhibiteurs de pan-kras et utilisations associées

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018008397B1 (pt) * 2015-11-09 2023-12-12 Astrazeneca Ab Composto, sal farmacêuticamente aceitável e formas cristalinas
EP3269365A1 (fr) * 2016-07-14 2018-01-17 Friedrich-Alexander-Universität Erlangen-Nürnberg Inhibiteur de kras destiné à être utilisé dans le traitement du cancer
JOP20190272A1 (ar) * 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
LT3710439T (lt) * 2017-11-15 2023-05-10 Mirati Therapeutics, Inc. Kras g12c inhibitoriai
CN112830928A (zh) * 2019-11-22 2021-05-25 四川海思科制药有限公司 一种嘧啶并环衍生物及其在医药上的应用
JP2023528903A (ja) * 2020-06-04 2023-07-06 アンテンジーン・ディスカバリー・リミテッド Ｋｒａｓ ｇ１２ｃタンパク質阻害剤およびその使用

Also Published As

Publication number Publication date
WO2022262797A1 (fr) 2022-12-22
CN117529321A (zh) 2024-02-06
TW202317130A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
PE20221504A1 (es) Derivados de un inhibidor de fgfr
CL2023000767A1 (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto.
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
MX2022002465A (es) Inhibidores de kras g12d.
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
AR054805A1 (es) Composiciones topicas para el tratamiento de la piel
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
IS6069A (is) N-cýanómetýlamíð sem próteasalatar
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
PH12019550249A1 (en) Solid compositions for oral administration
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
CO2024006819A2 (es) Composiciones y tratamientos con nirogacestat
AR126166A1 (es) Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos
WO2022221528A3 (fr) Inhibiteurs de kras g12c
ES2183817T3 (es) Inibidores de proteasas de parasatiso metazoarios.
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
CO2022015428A2 (es) Compuesto de oxofenilarsina deuterada y uso del mismo
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
AR128051A1 (es) Inhibidores de parp1
AU2017260019A1 (en) Valerian composition and related methods
CL2021001090A1 (es) Tratamiento y prevención de la eyaculación precoz (ep).

Legal Events

Date Code Title Description
FB Suspension of granting procedure